BridgeBio Oncology Therapeutics Insider Trades
NASDAQ: BBOTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 2 · $3.63K
- Shares bought / sold
- 0 / 1.95K
- Net activity
- Net selling $3,628
BridgeBio Oncology Therapeutics insider activity
Over the last 12 months, BridgeBio Oncology Therapeutics insiders reported 23 transactions on SEC Form 4: 0 open-market purchases and 2 sales. Insiders bought $0 and sold $3,628 worth of stock, for net insider selling of $3,628. The largest seller was Beltran Pedro, with $3,443 in reported sales.
The most recent filing shows Beltran Pedro (President and CEO) selling 1,870 shares at $1.84 on Nov 18, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put BBOT's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
BBOT insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Nov 18, 2026 | Beltran PedroPresident and CEO | Sale | 1,870 | $3.44K | Form 4 |
| Nov 13, 2026 | Cobo MarcPrincipal Accounting Officer | Sale | 78 | $184.86 | Form 4 |
| Oct 21, 2026 | Cobo MarcPrincipal Accounting Officer | Tax withholding | 203 | $544.04 | Form 4 |
| Oct 1, 2026 | Beltran PedroPresident and CEO | Tax withholding | 1,047 | $4.13K | Form 4 |
| Oct 1, 2026 | Ben YongChief Med & Dev Officer | Tax withholding | 1,047 | $4.13K | Form 4 |
| Oct 1, 2026 | Elmelech IdanCOO & Principal Financial Ofcr | Tax withholding | 343 | $1.35K | Form 4 |
| Oct 1, 2026 | Cobo MarcPrincipal Accounting Officer | Tax withholding | 126 | $496.44 | Form 4 |
| Sep 10, 2026 | Cobo MarcPrincipal Accounting Officer | Tax withholding | 203 | $1.12K | Form 4 |
| Sep 10, 2026 | Cobo MarcPrincipal Accounting Officer | Award | 9,038 | — | Form 4 |
| Jul 1, 2026 | Beltran PedroPresident and CEO | Tax withholding | 1,047 | $8.17K | Form 4 |
| Jul 1, 2026 | Ben YongChief Med & Dev Officer | Tax withholding | 1,047 | $8.17K | Form 4 |
| Jul 1, 2026 | Elmelech IdanCOO & Principal Financial Ofcr | Tax withholding | 343 | $2.68K | Form 4 |
| Jul 1, 2026 | Chen BihuaDirector | other | 130,865 | — | Form 4 |
| Jul 1, 2026 | Chen BihuaDirector | other | 1,704,862 | — | Form 4 |
| Jul 1, 2026 | Chen BihuaDirector | other | 2,692,459 | — | Form 4 |
| Jul 1, 2026 | Chen BihuaDirector | other | 4,528,186 | — | Form 4 |
| Jul 1, 2026 | Cobo MarcPrincipal Accounting Officer | Tax withholding | 125 | $975 | Form 4 |
| Apr 1, 2026 | Mehra UneekFormer Officer | Tax withholding | 524 | $4.73K | Form 4 |
| Apr 1, 2026 | Beltran PedroPresident and CEO | Tax withholding | 1,047 | $9.45K | Form 4 |
| Apr 1, 2026 | Ben YongChief Med & Dev Officer | Tax withholding | 1,047 | $9.45K | Form 4 |
| Mar 10, 2026 | Ben YongChief Med & Dev Officer | Award | 46,670 | — | Form 4 |
| Mar 10, 2026 | Mehra UneekChief Financial Officer | Award | 23,330 | — | Form 4 |
| Mar 10, 2026 | Beltran PedroChief Scientific Officer | Award | 46,670 | — | Form 4 |
| Oct 10, 2025 | BridgeBio Pharma LLC & BridgeBio Pharma, Inc.10% Owner | other | 784,720 | — | Form 4 |
| Aug 11, 2025 | Chen BihuaDirector | Award | 284,571 | — | Form 4 |
| Aug 11, 2025 | Chen BihuaDirector | Award | 1,762,760 | — | Form 4 |
| Aug 11, 2025 | Chen BihuaDirector | Award | 1,905,046 | — | Form 4 |
| Aug 11, 2025 | Chen BihuaDirector | Award | 5,598,425 | $60.00M | Form 4 |
| Aug 11, 2025 | Chen BihuaDirector | Award | 639,110 | $6.85M | Form 4 |
| Aug 11, 2025 | Chen BihuaDirector | Award | 760,496 | $8.15M | Form 4 |
| Aug 11, 2025 | Chen BihuaDirector | Disposition | 152,940 | — | Form 4 |
| Aug 11, 2025 | Chen BihuaDirector | Option exercise | 4,172,126 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4